MicroPort NeuroTech Limited ((HK:2172)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MicroPort NeuroTech Limited is conducting a clinical study titled ‘A Prospective, Multi-Center, Open-Label, Superiority, Randomized, Controlled Registration Trial of the Rapamycin Neurovascular Balloon Catheter for the Treatment of Symptomatic Cerebral Atherosclerotic Stenosis’. The study aims to evaluate whether the drug-coated balloon (DCB) is superior to the conventional balloon in treating cerebral atherosclerotic stenosis, a condition that narrows the arteries in the brain.
The intervention being tested is the Rapamycin Neurovascular Balloon Catheter, a drug-coated device designed to treat symptomatic cerebral atherosclerotic stenosis. It is compared against a conventional balloon to assess effectiveness.
This interventional study employs a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are allocated randomly to either the experimental group using the Rapamycin balloon or the control group using the conventional balloon.
The study began on November 8, 2024, which is also the date of the last update. Although the primary completion and estimated completion dates are not specified, the study is currently enrolling by invitation, indicating ongoing progress.
The outcome of this study could significantly impact MicroPort NeuroTech’s stock performance by potentially enhancing its market position if the Rapamycin balloon proves superior. Investors should watch for updates, as successful results may influence industry dynamics, particularly in the neurovascular device sector.
The study is ongoing, with further details available on the ClinicalTrials portal.